Medtech Firm Enovis Sets Strong 2024 Targets As Q4 Earnings Beat Expectations, Analyst Says Growth Intact
Medtech Firm Enovis Sets Strong 2024 Targets As Q4 Earnings Beat Expectations, Analyst Says Growth Intact
Enovis Corporation's (NYSE:ENOV) fourth-quarter net sales reached $455 million, up 11% Y/Y, including 8% organic growth, beating the consensus of $445.36 million.
伊諾維斯公司（紐約證券交易所代碼：ENOV）第四季度的淨銷售額達到4.55億美元，同比增長11％，包括8％的有機增長，超過了預期的4.4536億美元。
Fourth quarter results reflect continued execution in P&R, above-market growth in Recon, and the impact of recent acquisitions.
第四季度的業績反映了P&R的持續執行、Recon高於市場的增長以及最近收購的影響。
Compared to the same quarter in 2022, net sales in Recon grew 18%, with 11% organic sales growth, and P&R grew 8%, with 6% organic sales growth.
與2022年同期相比，Recon的淨銷售額增長了18％，有機銷售增長了11％，P＆R增長了8％，有機銷售增長了6％。
Also Read: This Analyst Sees Durable Share Gains, Margin Expansion For Orthopedics-Focused Enovis.
另請閱讀：這位分析師認爲，專注於骨科的Enovis的份額將持續上漲，利潤率擴大。
Enovis reported a fourth-quarter net income from continuing operations of $3 million and an adjusted EBITDA of $82 million, or 18% of sales, a decline of 30 basis points versus the comparable prior year quarter, which includes the temporary dilution of recent acquisitions.
Enovis報告稱，第四季度來自持續經營業務的淨收入爲300萬美元，調整後的息稅折舊攤銷前利潤爲8200萬美元，佔銷售額的18％，與去年同期相比下降了30個點子，其中包括對近期收購的暫時稀釋。
The company reported adjusted earnings per diluted share of $0.79, beating the consensus of $0.74.
該公司報告調整後的攤薄後每股收益爲0.79美元，超過市場預期的0.74美元。
"We are very pleased with our results in 2023, with both revenues and operating margins exceeding expectations while continuing to make investments in key growth initiatives and M&A," said Matt Trerotola, Chief Executive Officer of Enovis. "We look forward to carrying this momentum into 2024, which is setting up to be a transformative year as we integrate Lima and kick off a multi-year cadence of new product introductions across Recon and P&R."
Enovis首席執行官馬特·特雷羅托拉表示：“我們對2023年的業績感到非常滿意，收入和營業利潤率均超出預期，同時繼續投資關鍵增長計劃和併購。”“我們期待將這一勢頭延續到2024年，這將是變革性的一年，因爲我們將整合利馬，並在Recon和P＆R開始了爲期多年的新產品推出。”
Guidance: Enovis forecasts fiscal year 2024 revenue of approximately $2.05 billion-$2.15 billion versus a consensus of $2.12 billion.
指導：Enovis預測2024財年的收入約爲20.5億美元至21.5億美元，而市場普遍預期爲21.2億美元。
The guidance includes $290 million-$300 million of revenue related to the Lima acquisition, which closed on January 3, 2024.
該指導方針包括與利馬收購相關的2.9億至3億美元的收入，該收購於2024年1月3日完成。
It guided for an adjusted EBITDA of $365-$380 million, including $70-75 million from Lima.
它預計調整後的息稅折舊攤銷前利潤爲3.65-3.8億美元，其中包括來自利馬的7000萬至7500萬美元。
Full-year 2024 adjusted earnings per diluted share are expected to be $2.50-$2.65 versus consensus of $2.71.
2024年全年調整後的攤薄後每股收益預計爲2.50美元至2.65美元，而市場預期爲2.71美元。
William Blair says the integration of Lima has introduced various components affecting profit and loss. Despite this, initial analysis of the fourth-quarter results and 2024 guidance indicates that the expectation for sustained growth and enhanced margins is still valid.
威廉·布萊爾說，利馬的一體化引入了影響盈虧的各種組成部分。儘管如此，對第四季度業績和2024年指引的初步分析表明，對持續增長和利潤率提高的預期仍然有效。
William Blair maintains an "Outperform" rating for the shares, considering their current valuation at 11 times the estimated EBITDA for 2025.
考慮到這些股票目前的估值是2025年預計息稅折舊攤銷前利潤的11倍，威廉·布萊爾維持其股票的 “跑贏大盤” 評級。
Price Action: ENOV shares are up 7.56% at $64.83 on the last check Thursday.
價格走勢：在週四的最後一次支票中，ENOV股價上漲7.56％，至64.83美元。